950769-51-4

Usage

Uses

Used in Pharmaceutical Research:
N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)phenyl]urea is used as a research compound for exploring its potential biological activity and therapeutic effects. Its unique molecular structure makes it a valuable asset in the discovery of new drugs and treatments for various medical conditions.
Used in Drug Development:
In the pharmaceutical industry, N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)phenyl]urea is utilized as a lead compound in the development of new medications. Its properties may contribute to the creation of innovative therapies that address unmet medical needs.

Upstream product

• 1132827-30-5 4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)benzenamine 
• 55809-53-5 5-tert-butyl-3-isoxazolyl isocyanate 

Relevant academic research and scientific papers

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2- morpholin-4-yl-ethoxy)imidazo-[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor

Treatment of AML patients with small molecule inhibitors of FLT3 kinase has been explored as a viable therapy. However, these agents are found to be less than optimal for the treatment of AML because of lack of sufficient potency or suboptimal oral pharma

SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-{4-[7-(2-MORPHOLIN-4-YL-ETHOXY)IMIDAZO[2,1-B][1,3]BENZOTHIAZOL-2-YL]PHENYL}UREA, COMPOSITIONS THEREOF, AND USES THEREWITH

Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin- 4-yl-ethoxy)imidazo[2,l-b][l,3]benzothiazol-2-yl]phenyl}urea, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatmen

Imidazolothiazole compounds for the treatment of disease

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.